Table 1.
Patient and tumor characteristics
| Statistics | SD | PD | p |
|---|---|---|---|
| Total, n (%) | 64 (100%) | 44 (100%) | |
| iCTC count at baseline, median (range) | 15 (5–2760) | 30.5 (5–200,000) | 0.39 |
| aCTC−positive at baseline, n (%) | 43 (67.2%) | 27 (61.4%) | 0.53 |
| aCTC count at baseline, median (range) | 10.5 (0–1500) | 9 (0–800) | 0.475 |
| iCTC−positive after 1 cycle of syst. therapy, n (%) | 27 (42.2%) | 29 (65.9%) | 0.02 |
| iCTC count after 1 cycle of syst. therapy, median (range) | 2.5 (0–420) | 8.5 (0–15,000) | 0.001 |
| aCTC−positive after 1 cycle of syst. therapy, n (%) | 13 (20.3%) | 20 (45.5%) | 0.005 |
| aCTC count after 1 cycle of syst. therapy, median (range) | 1 (0–200) | 3 (0–250) | 0.01 |
| iCTC change, median (range) | −9.5 (−2748–90) | −7 (−185,000–816) | 0.172 |
| aCTC change, median (range) | −6 (−1498–129) | 0 (−800–239) | 0.005 |
| iCTC + aCTC Baseline | 30 (6–4260) | 43 (5–200,000) | 0.593 |
| iCTC + aCTC after 1 cycle | 4 (0–480) | 18 (0–15,000) | <0.001 |
| iCTC + aCTC change | 1 (−1246–460) | −3 (−185,000–1077) | 0.059 |
| Age at initial diagnosis, median (range) | 50 (32–81) | 48.5 (28–73) | 0.07 |
| Age at study enrollment, median (range) | 55.5 (36–81) | 55.5 (33–77) | 0.34 |
| ER−positive primary tumor, n (%) | 45 (73.8%, NA = 3) | 30 (73.2%, NA = 3) | 0.95 |
| HER2−positive primary tumor, n (%) | 14 (23.7%, NA = 5) | 4 (11.1%, NA = 8) | 0.128 |
| ER−positive metastasis, n (%) | 27 (81.8%, NA = 11) | 19 (73.1%, NA = 18) | 0.42 |
| HER2−positive metastasis, n (%) | 2 (6.3%, NA = 12) | 6 (21.4%, NA = 8) | 0.08 |
| Number of metastatic sites One site, n (%) Multiple sites, n (%) |
16 (25.0%) 48 (75.0%) |
8 (18.2%) 36 (81.8%) |
0.49 |
| Site of metastasis Bone, n (%) Viscera, n (%) |
51 (79.7%) 47 (73.4%) |
35 (79.5%) 33 (75.0%) |
0.99 0.86 |
| Metastatic systemic therapy lines First line, n (%) Second line, n (%) Other lines of therapy, n (%) |
13 (17.2%) 28 (43.8%) 25 (39.1%) |
5 (11.3%) 13 (29.5%) 26 (59.1%) |
0.12 |
| Metastatic chemotherapy lines First line, n (%) Second line, n (%) Other lines of therapy, n (%) |
16 (25.0%) 29 (45.3%) 19 (29.7%) |
8 (18.2%) 11 (25.0%) 25 (56.8%) |
0.02 |
| Median OS in months, median (range) | 23 (4–91) | 7 (2–43) | <0.001 |